Plus, the House passed the $484 billion small business aid package, consumer confidence fell for the third straight month, and AT&T’s Stephenson is out as CEO.
Read MoreBuy Price – $13.75 or better Sell Price – TradersPro Sell Signal Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company […]
Read MorePlus, oil rebounded, the Senate passed the $484 billion supplemental coronavirus relief package, Delta reported its first quarterly loss in five years, and Chipotle said its digital sales more than doubled in Q1.
Read MoreBuy Price – $7.30 or better Sell Price – TradersPro Sell Signal NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; […]
Read MorePlus, oil fell back into negative territory this morning, Trump pledged aid for struggling oil and gas companies, Coca-Cola said its global volumes have plunged 25% so far this month, and Starbucks is adding Beyond Meat products to its menu in China.
Read MorePlus, the Trump administration unveiled guidelines for states to consider when reopening, China reported its first contraction in GDP since it began reporting the quarterly figure, and Procter & Gamble reported earnings.
Read MoreThe healthcare sector is on the rise and these 3 stocks in the group look like good best now.
Read MorePlus, negative bank earnings kept rolling in, coronavirus cases surpassed 2 million globally, Abbott Laboratories released a new COVID-19 antibodies test, and Apple released a new, budget-friendly iPhone.
Read MoreTrade Setup Buy Target $2.26 Sell Target $2.97 Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated […]
Read MoreInvestors, like the entire the market, and like all of us seem anxious to find some kind, any kind of reason to see hope in the future – either for the prospect of seeing some form of a “return to normal” for the U.S. at large. Get the kids going back to school, churches open […]
Read MoreThese 4 names are making big strides in treatments and vaccines for the the coronavirus.
Read MorePlus, the Trump Administration is reportedly launching a new coronavirus task force focused on the economic devastation caused by the pandemic, oil rose on reports Saudi Arabia and Russia have come to agreement on a massive production cut, and airline stocks are on the rise after Mnuchin said airlines could hear back on their applications for government aid by as soon as tomorrow.
Read MoreTrade Setup Buy Target $7.55 Sell Target $10.14 Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the […]
Read MorePlus, JPMorgan’s Jaime Dimon said the coronavirus crisis will produce a “bad recession,” oil is lower as the OPEC+ meeting to discuss a production cut is delayed, and Apple said it will deliver 1 million face shields per week starting this week.
Read MoreBuy Target – $1.10 or better Sell Target – TradersPro Sell Signal electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the […]
Read More